Form 4: Tvardi Therapeutics Director Acquires Shares Through Merger

Wallace L Hall Jr., a director of Tvardi Therapeutics, acquired shares of common stock through a merger and conversion of preferred stock and convertible notes.

Summary

• Wallace L Hall Jr., a director of Tvardi Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The transactions occurred on April 15, 2025, as a result of the merger between Cara Therapeutics, Inc. (now Tvardi Therapeutics, Inc.) and CT Convergence Merger Sub, Inc.
• Hall acquired 44,712 shares of common stock indirectly through Firepit Partners, LP, and 202,044 shares indirectly through BioMatrix Partners Ltd.
• These shares were received in exchange for Series A and Series B Preferred Stock of Legacy Tvardi and common stock issuable upon exchange of convertible notes, pursuant to the merger agreement.
• Hall disclaims beneficial ownership of the shares held by Firepit and BioMatrix except to any pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider ownership.

Key Dates

Keywords

Tvardi Therapeutics, Form 4, Beneficial Ownership, Merger, Director, Shares, Stock, Convertible Notes, Preferred Stock, Firepit Partners, BioMatrix Partners